References
  1. Orazi A, Hasserjian RP, Cazzola M, Thiele M, Malcovati L., Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, International Agency for Research on Cancer. 2017; 93-94.
  2. Swerdlow SH, Campo E, Harris NL, et al, ed. WHO classification of tumours of haematopoietic and lymphoid tissues, Lyon, France: International Agency for Research on Cancer, 2017.
  3. Broseus J, Florensa L, Zipperer E, et al. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica 2012; 97:1036-1041.
  4. Jeromin S, Haferlach T, Weissmann S. “Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1mutations”, Haematologica. 2015; 100: pp. e125-e127.
  5. Patnaik MM, Tefferi A, Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) – 2021 update on diagnosis, risk-stratification, and management. Am J Hematol . 2021; 96: 379–394.
  6. Visconte, V., Avishai, N., Mahfouz, R. et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia . 2015; 29: 188–195.
  7. Oh ST, Gotlib J,  JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology . 2010; 3: 323-337.
  8. Pati, H, Veetil KK. Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications. Indian J Hematol Blood Transfus.  2019; 35: 3–11.
  9. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in 206 myeloproliferative neoplasms. N Engl J Med.2013; 369:2379–2390.
  10. J. Broséus, E. Lippert, A.S. Harutyunyan, et al. “Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis”. Leukemia , 2014; 6: 1374–1376.
  11. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other 209 myeloid disorders: a study of 1182 patients. Blood . 2006;108: 3472–3476.
  12. S. Schnittger, U. Bacher, C. Haferlach, et al. “Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis”, Leukemia , vol. 22, no. 2, pp. 453–455, 2008.
  13. Ernst T, Chase AJ, Score J, et al. Inactivating 212 mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet . 2010; 42: 22–213.
  14. Abdel-Wahab O, Adli M, LaFave et al., ASXL1 mutations 216 promote myeloid transformation through loss of PRC2-mediated gene repression.Cancer Cell. 2012; 22:180–193.
  15. Figueroa ME, Abdel-Wahab O, Lu C, et al., Leukemic IDH1 and 220 IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic 221 differentiation. Cancer Cell . 2010; 18: 553–567.
  16. Broseus J, Florensa L, Zipperer E, et. al. Clinical features 183 and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica . 2012; 97: 1036–41.
  17. van Genderen PJJ,  Michiels JJ. Erythromelalgia: A pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 1997; 23: 357-363.
  18. Patnaik MM, Lasho TL, CM , et al., Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. Leukemia . 2016; 30: 2273-2275.
  19. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm. 2018. Blood Cancer J. 2018; 10: 2.
  20. Alvarez-Larran A, Cervantes F, Pereira A, et al., Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood . 2010; 116:1205-1210.
  21. Pascale S, Petrucci G, Dragani A, et al., Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood . 2012: 119: 3595-3603.
  22. Awada H, Voso MT, Guglielmelli P, Gurnari C. Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers . 2020; 12:1746.
  23. Nicolosi M, Mudireddy M, Vallapureddy R, et. al., Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)”, Am J Hematol . 2018; 93: pp. E27-E30.
  24. G. Huls, A.B. Mulder, S. Rosati, A.A. van de Loosdrecht, E. Vellenga, J.T. de Wolf. “Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis”. Blood . Vol.116, no.2, pp. 180-182, 2010.
  25. M.M. Patnaik, A. Tefferi, “Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management”, Am J Hematol . 2017;Vol. 92: 297–310.
  26. Moyo V, Lefebvre P, Duh MS, et. al. Erythropoiesis- stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol . 2008; 87:527-536.
  27. Komorkji RS, Luspatercept in Myelodysplastic Syndromes: Who and When?Hematol Oncol Clin North Am. 2020; 34: 393-400.
  28. Sharma P, Shinde SS, Damlaj M, et al., Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/ myeloproliferative neoplasm (MDS/MPN) overlap syndromes. Leuk Lymphoma . 2016; 58: 872-881.